Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma 2Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 6Cyclophosphamide 6X-Rays 5Phantoms, Imaging 5Filgrastim 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Gemcitabine 4Biopsy 4tazemetostat 3Surveys and Questionnaires 3Psychiatric Rehabilitation 3Etoposide 3Drug Therapy 3Carboplatin 3Busulfan 3Bevacizumab 3ulixertinib 2tipifarnib 2spartalizumab 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2ganitumab 2ensartinib 2aflibercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Tetanus Toxoid × Lymphoid × Clear all
NCT01644968 2022-05-17

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Providence Health & Services

Phase 1 Completed
30 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡